Introduction
Prediction modeling has long been a mainstay of statistical practice. The field has been re-energized recently due to the promising identified through imaging and molecular biotechnologies. Accordingly, there has been renewed interest in methods for evaluating the performance of prediction models. In particular, statisticians have been examining methods for evaluating improvement in performance that is gained by adding a novel marker to a baseline set of predictors.
For example, novel markers for predicting risk of breast cancer beyond traditional factors in the Gail model [1, 2] include breast density [3, 4] and genetic polymorphisms [5, 6, 7] . For cardiovascular outcomes, numerous studies have been performed in recent years to evaluate candidate markers for their capacities to improve upon factors in the standard Framingham risk score [8] . Tzoulaki et al. [9] recently performed a meta-analysis of 79 such published studies.
A typical approach to analysis is to first determine the statistical significance of an observed association between the novel marker, Y , and the outcome, D, controlling for the baseline predictors that we denote by X. The p-value is usually derived from regression modeling techniques. If the contribution of Y to the risk model is found to be statistically significant, the second step in the typical approach is to test a null hypothesis about improvement in prediction performance for the model that includes Y in addition to X compared with the baseline model that includes only X. The most popular statistic for testing improvement in prediction performance is the change in the area under the receiver operating characteristic (ROC) curve [9] . Alternate measures are also used, including risk redistribution metrics [10, 11] and risk reclassification metrics [12, 13, 14, 15, 16] .
In this paper we question the strategy of testing the null hypothesis about no improvement in prediction performance after testing the statistical significance of Y in the risk model. Our main theoretical result is that the null hypotheses are equivalent. This implies that if Y is shown to be a risk factor, the prediction performance of the model that includes Y cannot be the same as the performance of the baseline model, and there is no point to a second, redundant hypothesis test.
In Section 2 we prove our main result that the null hypothesis about Y as a risk factor can be expressed equivalently as a variety of null hypotheses about the improvement in performance of the expanded model compared with the baseline model. In Section 3 we discuss the choice of methodology for testing the common null hypothesis. We recommend use of standard statistics derived from regression modeling of the risk as a function of X and Y . This recommendation is based partly on the superior power achieved with likelihood based tests, but also on the new finding corroborated by other recent reports in the literature [14, 17] , that standard ROC methods for nested models appear to be excessively conservative. We emphasize that estimation of the increment in prediction performance is more important than testing the null hypothesis of no improvement. The results are discussed in Section 4 in the context of a real dataset concerning risk of renal artery stenosis as a function of baseline predictors and a biomarker, serum creatinine.
Equivalent Null Hypotheses
Suppose that the outcome is binary, D = 1 for cases or D = 0 for controls, which could represent occurrence of an event within a specified time period, say breast cancer within 5 years. Let risk(X) = P (D = 1|X) and risk(X, Y ) = P (D = 1|X, Y ) be the baseline and enhanced model risk functions respectively. To evaluate the incremental value of Y for prediction over use of X alone, the first step is often to test the null hypothesis
We use subscripts (X, Y ) and X to indicate entities relating to use of risk(X, Y ) and risk(X), respectively. For example, ROC (X,Y ) is the ROC curve for risk(X, Y ) while ROC X is the ROC curve for risk(X). The ROC curve for W is a plot of P (W > w|D = 1) versus P (W > w|D = 0) and is a classic plot for displaying discrimination achieved with a variable W [18] (Chapter 4). To test if discrimination provided by risk(X, Y ) is better than that provided by risk(X), one could test
In ROC analysis the area under the ROC curve (AUC) is typically used as the basis of a test statistic. Then the null hypothesis is more specifically stated as
In the ROC framework another approach is to assess if, conditional on X, the ROC curve for Y is equal to the null ROC curve [19] . This is particularly relevant when controls are matched by design to cases on X [20] . The corresponding null hypothesis is
Several authors have proposed alternatives to ROC analysis for comparing nested prediction models. The predictiveness curve displays the distribution of risk as the risk quantiles [10, 21, 22] . We write the cumulative distribution of risk as
One can test if the risk distributions based on X or on (X, Y ) are different by testing the null hypothesis
Another view is to consider the risk distributions in the case population (denoted with superscript D) and in the control population (superscriptD), separately. We could test
The integrated discrimination improvement statistic is a summary measure based on the difference in average risks between cases and controls, MRD = E(risk(·)|D = 1) − E(risk(·)|D = 0). The MRD has many interpretations, for example as the proportion of explained variation, as an R 2 statistic, as Yates slope, and as an average Youden's index [15, 23, 24] . Pencina and others [12] define the integrated discrimination improvement (IDI) as IDI = MRD (X,Y ) − MRD X and propose testing H 0 : IDI = 0. That is, they propose testing
Another interesting summary of the difference between the case and control risk distributions concerns proportions with risk above the average population risk, ρ = P (D = 1). The above average risk difference is AARD = P (risk(·) > ρ|D = 1) − P (risk(·) > ρ|D = 0). Like the MRD, the AARD has multiple interpretations and relates to existing measures of prediction performance. The AARD is the continuous net reclassification index (NRI (>0), defined below) statistic [13] for comparing a risk model with the null model that has no predictors in which all subjects are assigned risk P (D = 1) = ρ. The AARD is also equal to the two-category NRI for comparing a model with the null model when the two risk categories are defined as: low risk≡'risk≤ ρ' and high risk≡'risk> ρ'. The AARD can also be considered as a measure relating to the risk distribution in the population, F in equation (5) . In particular Bura and Gastwirth [25] defined the total gain statistic as the area between the predictiveness curve for risk(·) and the horizontal line at ρ, which is the predictiveness curve for the null model. Gu and Pepe [24] showed that the standardized total gain, total gain/2ρ(1−ρ), is ρAARD. One can compare the performance of two risk models by evaluating the AARD values and testing the null hypothesis
The medical decision making framework has also been used to compare risk models. Vickers and Elkin [26] suggested use of decision curves that plot the net benefit (NB(t)) ≡ ρP (risk(·) > t|D = 1) − (1 − ρ) P (risk(·) > t|D = 0) against t, the risk threshold. One could envision testing the equality of decision curves
to compare performance of a model that includes Y with one that does not. Baker [27, 28] suggests standardizing the net benefit by the maximum possible benefit resulting in a relative utility measure. Testing equality of relative utility curves is the same as testing equality of decision curves in (9) . Risk reclassification methodology is yet another approach to comparing risk models. In this framework, for each individual indexed by ı, risk(X ı , Y ı ) is compared directly with risk(X ı ). The NRI statistic is a risk reclassification measure that has gained tremendous popularity since its introduction by Pencina and colleagues in 2008 [12] . The continuous NRI [13] is defined as
The final null hypothesis that we consider testing is
Our key result is that all of the null hypotheses in equations (1) through (10) are equivalent.
Theorem 1
The following null hypotheses are equivalent Pepe, Feng and Gu [23] write Equality of the case specific distributions implies that the case specific means are equal:
The case specific distribution of risk can be derived from the population distribution of risk using Bayes' theorem [29] .
A similar argument applies to the control specific distributions. Therefore equality of population risk distributions in H 
Using Bayes' theorem it follows that
and so
Huang and Pepe [30] derived the one-one mathematical relationship between the ROC curve for risk(·) and the predictiveness curve which characterizes the risk distribution. Therefore equality of ROC curves for risk(X, Y ) and risk(X) implies equality of the risk distributions, H We now show that equality of AUCs for risk(X, Y ) and risk(X) implies equality of the ROC curves, i.e.
, from which H 1 0 follows. A fundamental result from decision theory is that decision rules of the form 'risk(X, Y ) > c' have the best operating characteristics in the sense that when c is chosen to yield a false-positive rate f, f = P (r(X, Y ) > c(f)|D = 0), the corresponding true-positive rate t = P (r(X, Y ) > c(f)|D = 1) cannot be exceeded by another decision rule based on (X, Y ). This result follows from Neyman-Pearson [31] and is discussed in detail in McIntosh and Pepe [32] .
It follows that the ROC curve for risk(X, Y ) is at least as high at all points than the ROC curve for any other function of (X, Y ). In particular, the ROC curve for the function risk(X) cannot exceed ROC (X,Y ) (·) at any point. Therefore, if the areas under ROC (X,Y ) (·) and ROC X (·) are equal, the functions must be equal at all points. That is H In the Appendix, Theorem A.1 considers the entity If NB (X,Y ) (t) = NB X (t) ∀ t, then in particular we have equality at
so at t = ρ we have NB(ρ) = ρAARD. We show below that
The analogous statement when conditioning on X is that
So if NRI(> 0) = 0 it follows that for all X with probability 1 we have
The corollary to Theorem A.1 in the Appendix then implies that the ROC curve for Y conditional on X is the null ROC curve. That is, for all X with probability 1,
In other words H 4 0 holds, which in turn implies H 1 0 . To complete the proof we need to prove our assertion that P (risk(Y ) > ρ|D = 1) ≥ P (risk(Y ) > ρ|D = 0). Using Bayes' theorem this can be restated as
But this holds because we have a ≥ b,
Theorem 1 is a mathematical result involving the functions risk(X, Y ) and risk(X) and performance measures that are functionals of them. No modeling of the risk functions is assumed. In the next section we consider practical implications of Theorem 1 for data analysis in which models for risk(X, Y ) and risk(X) may be fit to data.
Recommendations for Hypothesis Testing
The equivalence of the various null hypotheses in Theorem 1 should not be confused with the equivalence of different hypothesis tests. Two tests can have the same null hypothesis but still be different tests and give different results on a dataset because they are based on different test statistics with different statistical properties. However, it does not make sense to test the same null hypothesis twice -a single test should be chosen. How does one choose the statistical test for the null hypothesis of no incremental value?
There are many possible choices, but we focus here on the choice between a test for the coefficient for Y in a regression model of the risk function risk(X, Y ) and the change in the AUC for the ROC curves associated with estimated risk functions, risk(X) and risk(X, Y ). To make the discussion concrete we consider the Wald test based on β Y where β Y is the coefficient for Y in a model for risk(X, Y ) and a test based on the difference ∆ AUC = AUC (X,Y ) − AUC X where AUC is calculated with the empirical distributions of the fitted values for the risk function in subjects with D = 1 and D = 0.
Testing the regression coefficient has highest power
When the data are independent identically distributed observations, the Wald test is asymptotically the most powerful test for testing H 1 0 − H 10 0 , and so, at least in this classic setting, the test based on β Y is to be preferred. We see the power advantage demonstrated in the second row of the simulation results in Table 1 where the procedure based on ∆ AUC is fixed to have size equal to the nominal level of 0.05. It is also instructive to consider the special case where there are no baseline covariates. In that setting ∆ AUC is equivalent to the nonparametric two-sample Wilcoxon statistic while β Y from a linear logistic risk model is asymptotically equivalent to the difference in means and so is equivalent to a two-sample Z-statistic. The Z-statistic is well known to have superior performance compared with the Wilcoxon statistic for normal data. That is, testing using β Y is well known to be superior to testing using ∆ AUC for normally distributed data and no baseline covariates.
Standard tests of performance measures may not be valid
From a practical point of view, there are additional issues that make the Wald test more desirable than the ∆ AUC test. In particular, procedures for fitting risk regression models and for testing coefficients in regression models are highly developed. In contrast, surprisingly little work has been done regarding inference for the ROC performance of nested models. The typical approach to testing with ∆ AUC uses the fitted values for risk(X, Y ) and risk(X) as data inputs to a test of equal AUCs for two diagnostic tests such as the DeLong test [33] or the resampling based test [34] . The fact that the coefficients in the fitted values are estimated from the data is ignored in these testing procedures.
We used simulation studies to investigate the properties of these tests in a simple scenario. We generated data for X and Y as independent and normally distributed with standard deviation 1 in cases (D = 1) and controls (D = 0). The mean of X was 0.74 in cases and 0 in controls yielding an AUC of 0.7 for the baseline risk model. The mean of Y was 0 in cases and in controls under scenarios simulating the null setting for evaluating size, while the means were 0.37 or 0.74 in cases and 0 in controls under scenarios simulating the alternative setting for evaluating power. We see from the third and fourth rows in Table 1 that standard tests ignoring sampling variability in the estimated risk regression coefficients are extremely conservative. Both the DeLong test [33] that uses the normal approximation and a standard error formula and the test using percentiles of the bootstrap distribution [34] have size less than .005 with sample sizes as large as 100 cases and 900 controls. The conservatism is due to estimating the coefficients in the nested models since the same tests comparing X alone to another independent marker with equal performance were not conservative with comparable sample sizes (data not shown).
We implemented an alternative version of the ∆ AUC test in the hope that acknowledging sampling variability in the estimated regression coefficients would lead to a test with correct size. This approach used the bootstrap. We resampled observations from the original dataset, fit the risk models, and calculated ∆ AUC for each resampled dataset. Tests using percentiles of the bootstrap distribution (results shown in line 5 of Table 1 as ∆ AUC-adjusted) or the standard deviation of the bootstrap distribution (results not shown) remained conservative, though they were less conservative than procedures not adjusting for variability in regression coefficients. We conclude that all currently available procedures for testing incremental value based on ∆ AUC are unacceptably conservative in the classic scenarios we studied. From Table  1 we observe that as a consequence they have extremely low power compared with the Wald test for β Y .
What if models are not well calibrated?
The results of Theorem 1 have implications for the analysis of data when the functional form of risk(X, Y ) is approximately correct. That is, for testing the null hypothesis of no improvement in prediction performance the theorem implies that we can test if regression coefficients for Y are zero, but this requires that the regression model for risk(X, Y ) is correctly specified at least under the null. If the form of the regression model for risk(X, Y ) under the null is in doubt, i.e., if risk(X) is misspecified, tests based on the regression model may not be valid.
With misspecified model forms one might still use the risk modeling exercise to generate combination scores, risk * (X, Y ) and risk * (X). Under these circumstances we believe that a case can be made for considering tests of increment in performance using statistics based on performance measures such as ∆AUC instead of tests based on the regression coefficient for Y . Note that with this approach one should derive the combination scores in a training set and test for equality of performance in an independent test dataset since our simulation results (Table 1) and others [14, 17] show that current testing procedures are not valid if both steps are undertaken in the same dataset. It is our opinion however that poorly calibrated models are not acceptable in the context of risk prediction research. It is unethical to apply a model known to be poorly calibrated when calculating a person's risk. The assessment of calibration must be a priority and should precede assessment of prediction performance. A minimum requirement is weak calibration defined by :
so that of persons whose risks are calculated as r, approximately a proportion r are cases. If a model is poorly calibrated in the weak sense, it is simply not valid for the population and its performance characteristics are of less interest. One can and should at least recalibrate the models to the study population. The performance characteristics of the recalibrated models in the study population will then be of interest and can be assessed.
Recommendation
Our recommendation is to ensure the use of well calibrated risk models and to base hypothesis testing on β Y rather than on ∆ AUC. Procedures based on ∆ AUC do not have correct size. Kerr et al [35] found similar problems for the IDI statistic under the null. It is possible that new approaches to testing based on ∆ AUC could be developed to properly account for sampling variability in the fitted risk values and thereby yield appropriately sized tests. However, even if such procedures were developed, we have argued and observed in Table 1 (line 2) that tests based on β Y are still likely to be more powerful, at least when likelihood based procedures are used to estimate parameters in the risk models. Therefore testing based on β Y would still be the better choice.
More important than testing if there is any increment in prediction performance is estimating the size of the gain in performance. The sizes of the regression coefficients for Y and X in risk(X, Y ) are not sufficient because prediction performance depends on the population distribution of the predictors (X, Y ) in addition to the conditional probability function P (D = 1|X, Y ) = risk(X, Y ). A variety of measures to quantify the prediction performance of a risk model were described in Section 2 and a comparison of the measures calculated with risk(X) and risk(X, Y ) constitutes the corresponding increment in performance due to Y . The field of risk prediction has not yet settled debates about which are the best measures for quantifying performance increment and we do not debate this question further here. Our recommendation is to focus on estimating a compelling measure of increment in prediction performance. Any testing should be limited to testing whether Y is a risk factor when controlling for X in a regression model.
Application to a Renal Artery Stenosis Dataset
Diagnosis of stenosis in the renal artery involves a risky surgical procedure and is only undertaken for patients deemed likely to have a positive finding. The risk of having renal artery stenosis is estimated from clinical data in order to guide decisions about undergoing invasive surgery for definitive diagnostic procedures. Data for 426 patients who were surgically assessed for renal stenosis were reported by Janssens and others [36] . We consider the improvement in prediction performance that is gained by adding serum creatinine to the baseline predictors.
We randomly chose one third of the observations (n = 142) to generate a baseline risk predictor X that is a combination of the candidate clinical variables. Using linear logistic regression we found that age, body mass index (BMI) and abdominal bruit (bruit) were highly significantly associated with renal stenosis but that gender, hypertension and vascular stenosis were not. We refit the model including only age (in years), BMI (kg/m 2 ) and bruit (yes=1, no=0) to derive the linear combination X = 0.93 × age − 0.24 BMI + 1.58 × bruit.
We then evaluated the performances of risk models based on X and on the combination of X and Y = log (serum creatinine) using the remaining two thirds of the data (n = 284).
Linear logistic models were fit: The Wald test for H 0 : β 2 = 0 is highly significant with p < 0.001 (Table 2 ). According to Theorem 1 we can conclude that prediction model performance is improved by addition of Y to the model. Nevertheless we implemented tests based on ∆AUC as well to compare inference. The test for equality of AUCs is also significant but with much weaker p-value, p = 0.014, using the DeLong variance formula and p = 0.012 using percentiles of the bootstrap distribution. Recall that these tests do not acknowledge variability in the estimated regression coefficients ( β 1 , β 2 ) and are extremely conservative. Bootstrapping that incorporated refitting the risk model in each resampled dataset yielded a stronger p-value (p <0.001). However, in accordance with our recommendation in Section 3, the test based on β 2 yielded the strongest evidence that prediction performance is improved by including serum creatinine as a predictor.
We repeated the analysis using a weaker marker, Y * , for illustration. Here Y * = Y + ε where ε is a standard normal random variable, adding noise to Y . In this analysis the coefficient for Y * is highly statistically significant (p = 0.009, Table 2 ) while the standard tests based on ∆AUC are not (p = 0.12 using the DeLong variance formula and p = 0.13 using percentiles of the bootstrap distribution). The bootstrapped adjusted ∆AUC test that refits the models is significant, p = 0.02, but not as convincing as the test for Y * in the risk model (p = 0.009). Again, this is consistent with our simulation results and theoretical expectations and supports our recommendation for testing the null hypothesis of no performance improvement on the basis of the regression coefficient for Y in the enhanced risk model, risk(X, Y ).
Estimates of prediction performance are shown in Table 3 for the baseline and enhanced risk models. Confidence intervals were calculated using 2.5 th and 97.5 th percentiles of bootstrap distributions with models refit in each bootstrapped dataset. We estimated that the area under the ROC curve increased from 0.78 to 0.82 with addition of serum creatinine. We also considered a point on the ROC curve. In particular, setting the risk threshold so that 80% of the cases are sent for the invasive diagnostic renal arteriography, we find that the proportion of controls who unnecessarily undergo the procedure, denoted by ROC −1 (0.8) in Table 3 , decreases from 0.44 to 0.31. Note that Pfeiffer and Gail [37] recommend calculating the percent needed to follow (PNF) that is a simple function of ROC
. Therefore the PNF decreased from 0.55 to 0.45. The IDI statistic is the change in the MRD statistic and is calculated as 0.06 while the conceptually similar change in the AARD is 0.03. The continuous-NRI statistic is NRI(> 0) = 0.54. Note that the NRI is measured on a scale from 0 to 2, unlike most other measures that are restricted to (0,1). We calculated the net benefit using a risk threshold of 0.25. This threshold implicitly assumes that the net benefit of diagnosis for a subject with renal artery stenosis is 3 times the net cost of the diagnostic procedures for a subject without stenosis since the cost-benefit ratio = risk threshold/(1-risk threshold) [26] . The maximum possible benefit of a risk model in this population would be that associated with diagnosing all 67 (24%) subjects who have renal stenosis and not sending any controls for the diagnostic procedure. We calculate that the net benefit is 27.1% of maximum with use of the baseline model and 36.4% of maximum with use of the model that includes serum creatinine. We see that 95% confidence intervals for some but not all measures of improvement in performance exclude the null value of 0. However the single test of H 0 : β 2 = 0 is sufficient to conclude that performance is improved.
Discussion
The main result of this paper is that the common practice of performing separate hypothesis tests, for the coefficient of Y in the risk prediction model and for the change in performance of the model, is literally testing the same null hypothesis twice. Vickers et al. [17] make a heuristic argument for this point. We have proven the result with formal mathematical theory. Testing the same null hypothesis in multiple ways is poor statistical practice and should be replaced with a more thoughtful strategy for analysis that employs a single test of the null. Arguments in favor of basing the single test on the regression coefficient for Y in a risk model include: (i) that such tests are most powerful asymptotically; and (ii) that techniques are well developed and widely available for performing such tests. This strategy relies on employing risk models that have approximately correct forms. We have argued that good calibration is a crucial aspect of risk model assessment. If necessary models should be recalibrated to the population of interest prior to assessing model performance. After recalibrating the models, testing based on regression coefficients is the most powerful and reliable approach to detecting if there is any improvement in predictor performance by adding a predictor to a baseline model.
After testing if there is any improvement in prediction performance, the next task is to estimate the extent of improvement achieved. How to quantify the improvement in performance is a topic of much debate in the literature. A multitude of metrics exist, including ∆AUC, ∆MRD, ∆AARD, approaches based on risk reclassification tables [13, 15, 16] , approaches based on the Lorenz curve [37] and approaches based on medical decision making [7, 26, 28, 39] . This paper does not seek to provide guidance on the choice of measure, but we do emphasize that estimation of the improvement gained is crucial. Moreover, if hypothesis testing based on performance measures is employed, it should be with regard to a null hypothesis concerning minimal improvement, H 0 : performance improvement ≤ minimal rather than any improvement, H 0 : performance improvement = 0. The exercise of setting standards for minimal improvement may have the added benefit of helping us to choose a clinically relevant measure of performance improvement. (X,Y ) at t = a and with derivative higher than ROC (X,Y ) over (a, b). Therefore this ROC curve exceeds ROC (X,Y ) over (a, b). But this is impossible because the Neyman-Pearson lemma implies that ROC (X,Y ) (t) is optimal at all t. In particular ROC (X,Y ) (t) ≥ ROC X (t) at all t.
Recall from above that 0 = ROC (X,Y ) (t ρ ) − ROC X (t ρ ) = t ρ 0 (ROC (X,Y ) (t) − ROC X (t))dt.
But having shown that the integrand is ≥ 0, we must conclude that the integrated is 0, ROC (X,Y ) (t) = ROC X (t) ∀ t < t ρ .
Moreover equality of ROC (X,Y ) (t) and ROC X (t) at t = 0 and at t = t ρ implies ROC (X,Y ) (t) = ROC X (t) ∀ t < t ρ .
Similar arguments show that ROC (X,Y ) (t) = ROC X (t) ∀ t > t ρ .
Corollary A.1 Let ROC ω (·) be the ROC curve for the risk function risk(ω) = P (D = 1|ω). We show that ROC ω (t where t r ω = P (risk(ω) > r|D = 0). When ROC (t ω (r)) = 1 therefore, P (D = 1|risk(ω) = r) = ρ. That is, the point that maximizes ROC ω (t) − t is t ρ ω . We write sup|ROC ω (t) − t| = ROC ω (t ρ ω ) − t ρ ω (A.3) but (A.2) then implies that sup|ROC ω (t)−t| = 0. In other words ROC ω (t) = t ∀ t ∈ (0, 1). Note that equation (A.3) also follows from the fact that both sides of (A.3) were show to equal the standardized total gain statistic (see equations (6) and (7) of Gu and Pepe [24] ).
